SOUTH SAN FRANCISCO, Calif., Jan. 22, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that preclinical data for its lead immuno-oncology therapeutic candidate, CB-1158 has been selected for an oral presentation at the 2016 Keystone Symposia on Cancer Immunotherapy taking place January 24-28, 2016, in Vancouver, Canada. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a key immunosuppressive enzyme that limits T-cell proliferation in a wide range of tumors. Details for the presentation are as follows:
Arginase Inhibitor CB-1158 is a Novel Immuno-Oncology Agent that Targets Tumor-Infiltrating Suppressive Myeloid Cells
Date: January 27, 2016
Session: Novel Immunotherapeutic Approaches and Antibody Therapies
Time: 5:00 p.m. -7:00 p.m. PT
Presenter: Susanne Steggerda, Ph.D., Calithera Biosciences
Poster Display: 7:30 a.m. - 10:00 a.m. PT
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is currently being evaluated in three Phase 1 clinical trials in solid and hematological cancers. CB-1158 is a first-in- class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T -cells. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Calithera Biosciences, Inc.